{"nctId":"NCT00820027","briefTitle":"Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)","startDateStruct":{"date":"2008-12-15","type":"ACTUAL"},"conditions":["Pain, Postoperative"],"count":776,"armGroups":[{"label":"Etoricoxib 90 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etoricoxib 90 mg","Drug: Matching Placebo for Etoricoxib 120 mg","Drug: Matching Placebo for Ibuprofen","Drug: Morphine","Drug: Oxycodone"]},{"label":"Etoricoxib 120 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etoricoxib 120 mg","Drug: Matching Placebo for Etoricoxib 90 mg","Drug: Matching Placebo for Ibuprofen","Drug: Morphine","Drug: Oxycodone"]},{"label":"Ibuprofen 1800 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ibuprofen 600 mg","Drug: Matching Placebo for Etoricoxib 120 mg","Drug: Matching Placebo for Etoricoxib 90 mg","Drug: Morphine","Drug: Oxycodone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching Placebo for Etoricoxib 120 mg","Drug: Matching Placebo for Etoricoxib 90 mg","Drug: Matching Placebo for Ibuprofen","Drug: Morphine","Drug: Oxycodone"]}],"interventions":[{"name":"Etoricoxib 90 mg","otherNames":["MK-0663"]},{"name":"Etoricoxib 120 mg","otherNames":["MK-0663"]},{"name":"Ibuprofen 600 mg","otherNames":[]},{"name":"Matching Placebo for Etoricoxib 120 mg","otherNames":[]},{"name":"Matching Placebo for Etoricoxib 90 mg","otherNames":[]},{"name":"Matching Placebo for Ibuprofen","otherNames":[]},{"name":"Morphine","otherNames":[]},{"name":"Oxycodone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Is in generally good health and is scheduled to have a total knee replacement\n\nExclusion Criteria:\n\n* Is allergic, intolerant to, or has a history of a significant clinical or laboratory adverse experience associated with etoricoxib or other cyclooxygenase-2 (COX-2) inhibitors/non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen, morphine, or oxycodone, or has hypersensitivity to aspirin, or other NSAIDs\n* Has uncontrolled hypertension\n* Is currently a user of any illicit drugs, or has a history of drug or alcohol abuse within the past 5 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Placebo)","description":"The pain intensity difference was measured at rest over Days 1 through 3 in patients treated with etoricoxib (120 mg, 90 mg) compared to placebo for the treatment of pain following total knee replacement orthopedic surgery. Pain intensity difference at rest was measured on a numerical rating scale (NRS) from 0 - 10 points (0=no pain, to 10=pain as bad as you can imagine). Comparison to placebo was conducted in a step-down manner (the 90-mg dose was evaluated only if the null hypotheses for co-primary endpoints \\[Pain Intensity Difference (PID) and Morphine\\] 120-mg doses were rejected). The primary analyses for change from baseline in average pain intensity at rest over Days 1 to 3 was performed using the longitudinal data analysis (LDA) method with the terms for baseline pain intensity (moderate or severe), type of anesthesia (spinal or general), treatment, day, and the interaction of day by treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.93","spread":null},{"groupId":"OG001","value":"-3.87","spread":null},{"groupId":"OG002","value":"-3.39","spread":null}]}]}]},{"type":"PRIMARY","title":"Average Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Placebo)","description":"The average total dose of morphine was assessed when participant received etoricoxib 120 milligram(mg)/90 mg compared to placebo. Opioids taken were converted to mg morphine equivalents according to the following conventions: 1 mg morphine sulphate=1 mg morphine,1 mg morphine hydrochloride=1.17 mg morphine. A 5 mg oxycodone tablet=2.5 mg morphine,12.5 mg meperidine =1.67 mg morphine. Least-squares mean back-transformed; estimate obtained from longitudinal analysis of variance (ANOVA) model on log-transformed morphine dose with terms for baseline pain intensity(moderate or severe),type of anesthesia (spinal, general), treatment, day, and the interaction of day by treatment.","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.87","spread":null},{"groupId":"OG001","value":"9.25","spread":null},{"groupId":"OG002","value":"13.40","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least One Adverse Event of Congestive Heart Failure, Pulmonary Edema, or Cardiac Failure","description":"An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least One Edema-Related AE","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE. Edema is swelling caused by excess fluid trapped in body tissues.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"1.7","spread":null},{"groupId":"OG002","value":"1.8","spread":null},{"groupId":"OG003","value":"4.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least One Hypertension-Related AE","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"3.1","spread":null},{"groupId":"OG003","value":"3.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least One Opioid-Related AE","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE. Opioid-related AEs include nausea, vomiting, constipation, somnolence, respiratory depression, urinary retention and ileus.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null},{"groupId":"OG001","value":"36.5","spread":null},{"groupId":"OG002","value":"36.3","spread":null},{"groupId":"OG003","value":"41.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Ibuprofen)","description":"The pain intensity difference was measured at rest over Days 1 through 3 in participants treated with etoricoxib (120 mg, 90 mg) compared to ibuprofen for the treatment of pain following total knee replacement orthopedic surgery. Pain intensity difference at rest was measured on a numerical rating scale (NRS) from 0 - 10 points (0=no pain, to 10=pain as bad as you can imagine). Comparison to ibuprofen was conducted in a step-down manner (the 90-mg dose was evaluated only if the null hypotheses for co-primary endpoints \\[Pain Intensity Difference (PID) and morphine\\] 120-mg doses were rejected). The primary analyses for change from baseline in average pain intensity at rest over Days 1 to 3 was performed using the longitudinal data analysis (LDA) method with the terms for baseline pain intensity (moderate or severe), type of anesthesia (spinal or general), treatment, day, and the interaction of day by treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.93","spread":null},{"groupId":"OG001","value":"-3.87","spread":null},{"groupId":"OG002","value":"-3.83","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Total Daily Dose of Postoperative Morphine Over Days 1 to 3 (Etoricoxib vs. Ibuprofen)","description":"The difference in average total daily dose of morphine used over Days 1 through 3 between participants treated with etoricoxib (120 mg, 90 mg) or ibuprofen 1800 mg (administered as 600 mg three times daily, every 8 hours) in the treatment of pain following total knee replacement orthopedic surgery was assessed. Opioids taken were converted to mg morphine equivalents according to the following conventions:1 mg morphine sulphate = 1 mg morphine, 1 mg morphine hydrochloride = 1.17 mg morphine. A 5 mg oxycodone tablet = 2.5 mg morphine,12.5 mg meperidine = 1.67 mg morphine.","paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.87","spread":null},{"groupId":"OG001","value":"9.25","spread":null},{"groupId":"OG002","value":"8.82","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued Study Drug Due to an AE","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study product, is also an AE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"3.5","spread":null},{"groupId":"OG002","value":"4.5","spread":null},{"groupId":"OG003","value":"5.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":98},"commonTop":["Nausea","Vomiting","Constipation","Pyrexia","Insomnia"]}}}